Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
Authors' conclusion
Dual oral therapy was the most common treatment regimen at the start of second-line treatment, and over half of the participants remained on the same treatment during follow-up.
Study context
- Population
- Individuals with T2D initiating second-line glucose-lowering therapy, 37 countries11,592 with treatment data at baseline and 36 months
- Participants
- 14,687 individuals
- Exposure
- Baseline vs 36 months
- Outcome
- Glucose-lowering treatment regimens and HbA1c trajectories
- Follow-up
- 36 months
Methodological detailsdata analysis of the DISCOVER study programme, 3-year, 37 countries
- Data analysis of the DISCOVER study programme
- 3-year
- 37 countries
Main finding
As reported in the abstract
Treatment regimen use · baseline and 36 months
- Oral monotherapy: baseline vs 36 months
- 12.1% vs 12.4% (P = 0.22)
- Dual oral therapy: baseline vs 36 months
- 63.4% vs 47.6% (P < 0.0001)
- ≥ triple oral therapy: baseline vs 36 months
- 17.5% vs 25.4% (P < 0.0001)
- Injectable treatment: baseline vs 36 months
- 7.0% vs 13.7% (P < 0.0001)
- Changed treatment during follow-up
- 42.9%
Observational data: associations, not effects.
Further findings
Mmol/mol
- Mean HbA1c at baseline
- 67 (8.3%)
- Mean HbA1c at 6 months
- 55 (7.2%)
- Remained stable thereafter
- 11 882 with HbA1c data at baseline
Original publication
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study. Diabetes Obes Metab. Published 16 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →